Guess which ASX healthcare stock is up 31% on big news

What is getting investors excited on Tuesday? Let's find out.

| More on:
Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dimerix Ltd (ASX: DXB) shares are catching the eye of investors on Tuesday.

In morning trade, the ASX healthcare stock is up 31% to 46.5 cents.

Why is this ASX healthcare stock rocketing?

Investors have been fighting to get hold of the clinical-stage biopharmaceutical company's shares after it released a very positive announcement.

According to the release, Dimerix has entered into an exclusive development and license agreement with FUSO Pharmaceutical Industries.

FUSO Pharmaceutical Industries is a Japan-based pharmaceutical company that is engaged in the development, manufacture, and sale of basic pharmaceutical products that are essential for medical treatment. This includes dialysis solutions for artificial kidneys, infusions and injections, and products related to infertility treatment.

The two parties have signed an agreement for the development and commercialisation of the ASX healthcare stock's phase 3 drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan.

FUSO will be responsible for all development costs, submissions, and maintenance of the regulatory dossier with the Japanese Pharmaceutical and Medical Device Agency (PMDA), as well as all sales and marketing activities in Japan.

This is the third license deal executed for DMX-200 following deals with Advanz Pharma and Taiba. Dimerix will retain all rights to commercialise DMX-200 in all territories other than those covered by these license agreements.

What is DMX-200?

DMX-200 is currently in global phase 3 clinical development for treatment of FSGS kidney disease, with a blinded interim analysis anticipated in August.

If successfully developed, it could be a very lucrative product for the ASX healthcare stock.

As part of the agreement with FUSO Pharmaceutical Industries, Dimerix will receive a payment of 300 million yen (~A$3.1 million) within 40 days of executing the agreement, 400 million yen (~A$4.1 million) on initiation of the first clinical trial site (anticipated in Q1 2025), plus potential development and commercialisation milestones of up to 9.8 billion yen (~A$100 million).

Commenting on the agreement, the ASX healthcare stock's CEO and managing director, Dr Nina Webster, said:

We are delighted to partner with FUSO for the commercialisation of DMX-200 in Japan. FUSO brings a wealth of experience in pharmaceutical development and sales and marketing across Japan, and with a proven record in sales and marketing products for patients with renal disease.

This partnership reflects a confidence not only in the significant potential for DMX-200 in FSGS patients but also in Dimerix' capabilities in the development of DMX-200. FUSO's expertise and resources will be invaluable in supporting Dimerix to advance our shared goal of developing and commercialising DMX-200 and bringing hope to those patients desperately in need of treatment options.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Healthy gains: 5 best ASX 200 healthcare shares of 2024

Four of the five best-performing ASX 200 healthcare stocks of 2024 more than doubled in value.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why did the CSL share price go backwards in 2024?

CSL shares closed out 2024 in the red. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which All Ords ASX healthcare stock just surged 11% on FDA news

Investors are sending the ASX healthcare stock soaring on Monday.

Read more »

Healthcare Shares

Guess which ASX small cap stock is jumping on 'significant milestone'

This stock is ending the week in style. Let's see what is giving its shares a boost today.

Read more »

Healthcare Shares

Are CSL and this ASX 200 healthcare stock buys in January?

Is now a good time to pick up these shares? Let's see what analysts are saying.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Communication Shares

2 ASX shares expected to report strong earnings this quarter

Analysts expect a strong set of upcoming numbers for these ASX heavyweights

Read more »

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »